Cullinan Therapeutics (CGEM) Consolidated Net Income (2021 - 2023)
Historic Consolidated Net Income for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$25.6 million.
- Cullinan Therapeutics' Consolidated Net Income rose 555.66% to -$25.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$155.1 million, marking a year-over-year decrease of 24197.15%. This contributed to the annual value of -$167.6 million for FY2024, which is 804.25% down from last year.
- Per Cullinan Therapeutics' latest filing, its Consolidated Net Income stood at -$25.6 million for Q4 2023, which was up 555.66% from -$39.2 million recorded in Q3 2023.
- Cullinan Therapeutics' 5-year Consolidated Net Income high stood at $174.1 million for Q2 2022, and its period low was -$58.1 million during Q1 2023.
- In the last 3 years, Cullinan Therapeutics' Consolidated Net Income had a median value of -$25.2 million in 2022 and averaged -$9.4 million.
- The largest annual percentage gain for Cullinan Therapeutics' Consolidated Net Income in the last 5 years was 115885.39% (2022), contrasted with its biggest fall of 100627.2% (2022).
- Over the past 3 years, Cullinan Therapeutics' Consolidated Net Income (Quarter) stood at -$34.2 million in 2021, then rose by 20.87% to -$27.1 million in 2022, then increased by 5.56% to -$25.6 million in 2023.
- Its Consolidated Net Income stands at -$25.6 million for Q4 2023, versus -$39.2 million for Q3 2023 and -$32.2 million for Q2 2023.